Lippon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.90 M
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 138.29%
- Profit Growth 138.90%
- Ebitda 151.85%
- Net Worth 170.25%
- Total Assets 94.78%
About Lippon Pharma
Lippon Pharma Private Limited (LPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 04 June 2019 (Five years and eight months 24 days old ). Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M, as per Ministry of Corporate Affairs (MCA) records.
Venkatraman, Nazerkhan Alfin, Ramanathan Rajeshwari, and Three other members serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909TN2019PTC129735
- Company No.
129735
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Lippon Pharma?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatraman  | Director | 04-Jun-2019 | Current |
| Nazerkhan Alfin | Director | 04-Jun-2019 | Current |
| Ramanathan Rajeshwari | Director | 04-Jun-2019 | Current |
| Ramalingam | Director | 27-Nov-2023 | Current |
| Komala | Director | 14-May-2021 | Current |
| Kaliyaperumal Vadivel | Director | 04-Jun-2019 | Current |
Financial Performance of Lippon Pharma.
Lippon Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 138.29% increase. The company also saw a substantial improvement in profitability, with a 138.9% increase in profit. The company's net worth Soared by an impressive increase of 170.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lippon Pharma?
In 2021, Lippon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lippon Pharma?
Unlock and access historical data on people associated with Lippon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lippon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lippon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
